Hancock, MD , Sept. 28, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLFD) (the "Company") , the developer of Vitalzul™, a new generation of high potency veterinary cancer medications and nutraceuticals for pets, begins discussions with potential strategic partners with complimentary drug applications and new drug developments that will address the leading diseases in our companion pets thus expanding the product line of PetLife Pharmaceuticals.
The MoneyShow, Toronto (Canada), Sept 16-17, 2016
“As one of only a few publically traded company presenting at the Money show, PetLife Pharmaceuticals generated significant interest not only in their stock (OTCQB: PTLFD) but also in their private placement, which is available to accredited investors. Attendees were motivated by the opportunity to invest in a fully reporting company with a clear exit strategy for the individual investor, that being the public market” commented Dr. Salvagno, CEO of PetLife Pharmaceuticals.
Cavendish Global (Phoenix, Az), Sept 18-21, 2016
The Cavendish Global summit provided the opportunity for the company to present their portfolio in terms of its impact on global pet health via PetLife’s advancement of various potential methods of cancer cell apoptosis. Dr. Salvagno also presented the company’s flagship product, Vitalzul™, as means of “giving back” to animals for the benefit that pharmaceutical companies have received for use of animals in clinical trials. He noted “All of us in this room, whether we are performing or have performed clinical trials in animals, whether we have or will personally benefit from clinical trials in animals, now have the opportunity to do something to help solve the tragedy of cancer in our companion animals.”
In addition to being well received at Cavendish and identifying several strategic partners, PetLife Pharmaceuticals is in discussions with some leading scientists in joining our team to assist with both capital and building our intellectual property by expanding our treatment options consistent with the company’s mission of providing safe and effective solutions for critical diseases in companion animals.
Petlife’s 506 Private Placement Memorandum is available only to accredited investors.
About PetLife Pharmaceuticals, Inc.
PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.
PetLife's mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication, Vitalzul™, to the world of veterinary oncology -- with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.
Safe Harbor
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company, that are not purely historical are forward-looking within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company's business prospects and performance. The Company's actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company's filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.
Investor Relations: Invicto Group info@invictogroup.com 800-928-7462 Ext. 801
